indirubin sulfate
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2018 (NCT03614221)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cyclin-dependent kinase 2INHIBITOR
CDK2 inhibitor
Also potent against CDK1 and CDK4
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2- Mol. weight
- 241.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL258805 ↗
Also known as
- indirubin sulfate
- su-9516
- su-9516
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03614221 | Phase 2 | Aug 1, 2018 | Chang Gung University, Government of Taiwan |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chang Gung University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Government of Taiwan | Government | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1